An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)

Authors

Keywords

FDA, Regulatory, Alternative, Methodology, Approach, In vitro, Drug development

Journal

Volume 114, Issue -, Pages 104662

Publisher

Elsevier BV

Online

2020-04-21

DOI

10.1016/j.yrtph.2020.104662

Contact the author

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now